Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVX-012 for Mild-to-Moderate Dry Eye Syndrome
NCT03162094Phase 2Unknown
- Sponsor
- Avizorex Pharma
- Start
- Apr 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of STN1014100 in dry eye syndrome (DED) (7 arms), sponsored by Avizorex Pharma. Primary endpoints: Safety of AVX-012 ophthalmic solution at 1 week and Efficacy of AVX-012 ophthalmic solution in treating symptoms of dry eye at 4 weeks. Status: unknown.
02
Drugs
STN1014100
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT03162094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03162094.